Fig. 1

Rheumatoid Arthritis PreventIon of structural Damage 1 (RAPID1) and RAPID2 study design. Patients were randomized 2:2:1 to CZP 400 mg Q2W, CZP 200 mg Q2W, or placebo Q2W, respectively, in combination with MTX. The loading dose (LD) was CZP 400 mg at weeks 0, 2, and 4. ^aTwice the registered CZP dose. ^bRegistered CZP dose. ^cAt week 16, American College of Rheumatology 20% improvement nonresponders at weeks 12 and 14 were withdrawn from the RCTs; these patients, as well as those who completed the RCTs, were allowed to enter the OLEs, receiving CZP 400 mg Q2W + MTX for ≥ 6 months before being switched to CZP 200 mg Q2W + MTX. CZP Certolizumab pegol, Q2W Every 2 weeks, Q4W Every 4 weeks, MTX Methotrexate, RCT Randomized controlled trial, OLE Open-label extension